Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

47.72 +0.69 (+1.46%)
Streaming Delayed Price Updated: 2:47 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
1 Mooning Stock with Promising Prospects and 2 Facing Challenges
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
News headline image
1 Small-Cap Stock with Exciting Potential and 2 We Avoid
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows High Growth Momentum with Strong Technicals ↗
Discover how Collegium Pharmaceutical (COLL) combines a strong technical uptrend with powerful earnings growth, marking it as a high-potential stock. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q3 Earnings Call
Collegium Pharmaceutical’s third quarter was marked by robust demand for its ADHD medication Jornay PM and continued resilience in its pain management portfolio. Management pointed to a successful... 
Via StockStory
Topics Earnings
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
2 Momentum Stocks with Exciting Potential and 1 We Find Risky
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Credit Cards
News headline image
COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today
Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) jumped 11.6% in the morning session after the company reported strong third-quarter 2025 financial results, beating analyst... 
Via StockStory
Topics Economy Government World Trade
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Beats Q3 2025 Estimates and Raises Full-Year Guidance ↗
Collegium Pharmaceutical (COLL) beat Q3 2025 earnings estimates and raised its full-year guidance, driven by strong performance in its pain and ADHD portfolios. 
Via Chartmill
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1%
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know. 
Via StockStory
News headline image
3 Stocks Under $50 That Fall Short
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Artificial Intelligence
News headline image
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings?
Collegium Pharmaceutical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 10%. The stock now trades at $35.02, marking a 34.7% gain. This was partly thanks to... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
1 Russell 2000 Stock to Research Further and 2 We Avoid
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Safe-and-Steady Stock to Keep an Eye On and 2 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
1 Stock Under $50 Worth Investigating and 2 We Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
News headline image
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s... 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.